STITCH (Simplified Therapeutic Intervention To Control Hypertension)

Sponsor
University of Western Ontario, Canada (Other)
Overall Status
Completed
CT.gov ID
NCT00129909
Collaborator
Pfizer (Industry)
2,081
1
20
103.8

Study Details

Study Description

Brief Summary

The objective of this study is to assess whether the implementation of a primary treatment algorithm using a fixed dose combination therapy will improve the management of hypertension when compared to usual management.

Condition or Disease Intervention/Treatment Phase
  • Drug: fixed dose combination therapy
Phase 4

Detailed Description

There is a clear need for improved approaches for both improved blood pressure control and improved compliance with medication regimens. Although decreasing the frequency of drug taking does improve blood pressure control, whether fixed-dose combinations are more effective than taking multiple tablets is unknown. Additionally, notwithstanding the presence of excellent evidence-based recommendations for the treatment of hypertension, the choices for practitioners in regards to first line therapy is widening (and may be more confusing, especially in the setting of the proliferation of recommendations for a range of diseases). Whether a simplified treatment algorithm, consistent with the Canadian Hypertension Education Program (CHEP) guidelines but using a step-care approach, might improve management of hypertension is unknown. The current study will determine the effectiveness of a simplified treatment algorithm which incorporates early use of a fixed-dose combination therapy.

This is a cluster randomized controlled trial. Approximately 50 family practices eligible for study participation will be randomized in a 1:1 ratio to implement a treatment algorithm or to continue usual care for the management of hypertension. The randomization schedule will be stratified by the year of graduation of the family physician (< 1984 or ≥ 1984). Within each practice, 50 subjects will be managed according to the algorithm or usual care and will be followed for six months.

Study Design

Study Type:
Interventional
Actual Enrollment :
2081 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of a Primary Treatment Algorithm Using Fixed Dose Combination Therapy for the Management of Hypertension - Control and Intervention Arms
Study Start Date :
May 1, 2005
Actual Primary Completion Date :
Sep 1, 2006
Actual Study Completion Date :
Jan 1, 2007

Outcome Measures

Primary Outcome Measures

  1. The primary measure of outcome is the proportion of subjects treated to target (systolic blood pressure [SBP] <140 mmHg and diastolic blood pressure [DBP] <90 mmHg) at 6 months, compared at the practice level. []

Secondary Outcome Measures

  1. Secondary measures of response will include the change at 6 months in systolic blood pressure and diastolic blood pressure. These outcomes will be compared at the practice level []

  2. Provider satisfaction will be obtained by means of a questionnaire administered at each practice after the last study participant completes the study. []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female subjects 18 years or older

  • Hypertension SBP ≥ 140 mmHg or DBP ≥ 90 mmHg whether untreated or partially treated

  • Absence of ischemic heart disease, atrial fibrillation, peripheral vascular disease, stroke and chronic kidney disease

  • Not participating in other hypertension studies

  • Ability to give informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Robarts Research Institute London Ontario Canada N6A 5K8

Sponsors and Collaborators

  • University of Western Ontario, Canada
  • Pfizer

Investigators

  • Study Director: Ross D Feldman, MD, University of Western Ontario, Canada

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of Western Ontario, Canada
ClinicalTrials.gov Identifier:
NCT00129909
Other Study ID Numbers:
  • RPO402A; RPO402B
First Posted:
Aug 12, 2005
Last Update Posted:
Jun 14, 2012
Last Verified:
Jun 1, 2012
Keywords provided by University of Western Ontario, Canada
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 14, 2012